Pantelimon Iuliana, Gales Laurentia Nicoleta, Anghel Rodica Maricela, Gruia Maria Iuliana, Nita Irina, Matei Catalina Vali, Bodea Delia, Stancu Andra Maria, Pirvu Edvina, Radu Mihaela Corina, Dumitrescu Anca Irina, Manolescu Loredana Sabina Cornelia
Medical Oncology, Cantacuzino Hospital, Bucharest, ROU.
Oncology, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, Bucharest, ROU.
Cureus. 2022 Jul 17;14(7):e26952. doi: 10.7759/cureus.26952. eCollection 2022 Jul.
The influence of excess adipose tissue on the evolution and prognosis of breast cancer has been evaluated in numerous papers over the years. The ways in which obesity can influence the development, progression, and prognosis of this neoplasia are complex and requires the design of new studies, both clinical and preclinical. The aim of this study is to highlight a possible correlation between obesity-specific tumor microenvironment markers (adipokine or leptin) and the different histological subtypes and aggressive characteristics of breast tumors. We prospectively monitored the prognostic values of 39 patients diagnosed with breast cancer who received oncologic-specific treatment or are in follow-up regarding some obesity markers. Our analysis included parameters such as age, body mass index, immunohistochemical characteristics, and plasma concentration of leptin. The methodology was designed to reveal a possible correlation between obesity (quantified by measuring body mass index and waist circumference), the plasma level of leptin, and breast tumor immunohistochemical characteristics. The patients diagnosed with aggressive tumors subtypes (HER2-positive and triple-negative) had a significantly higher body mass index than patients diagnosed with luminal type tumors (32 kg/sqm versus 27 kg/sqm), the difference being 5 kg/sqm. In patients with non-luminal type breast tumors (HER2-positive and triple-negative), serum concentration of leptin is 55 pg/ml compared to 48 pg/ml in luminal type, statistically significant, p=0.0168. Leptin plays an important role in the connection of specific microenvironment tumors to breast cancer. An increased serum concentration of this adipokine was found in patients with HER2-positive and triple-negative breast tumors compared with luminal-type breast tumors, which could open new directions in the research of breast cancer prognosis in obese patients.
多年来,众多论文对过多脂肪组织对乳腺癌进展及预后的影响进行了评估。肥胖影响这种肿瘤发生、发展及预后的方式复杂,需要设计新的临床和临床前研究。本研究的目的是突出肥胖特异性肿瘤微环境标志物(脂肪因子或瘦素)与乳腺肿瘤不同组织学亚型及侵袭性特征之间可能存在的关联。我们前瞻性监测了39例接受肿瘤特异性治疗或处于随访中的乳腺癌患者某些肥胖标志物的预后价值。我们的分析包括年龄、体重指数、免疫组化特征以及瘦素的血浆浓度等参数。该方法旨在揭示肥胖(通过测量体重指数和腰围量化)、瘦素血浆水平与乳腺肿瘤免疫组化特征之间可能存在的关联。诊断为侵袭性肿瘤亚型(HER2阳性和三阴性)的患者体重指数显著高于诊断为管腔型肿瘤的患者(32 kg/m² 对 27 kg/m²),差值为5 kg/m²。在非管腔型乳腺肿瘤(HER2阳性和三阴性)患者中,瘦素血清浓度为55 pg/ml,而管腔型患者为48 pg/ml,具有统计学意义,p = 0.0168。瘦素在特定肿瘤微环境与乳腺癌的关联中起重要作用。与管腔型乳腺肿瘤患者相比,HER2阳性和三阴性乳腺肿瘤患者血清中这种脂肪因子浓度升高,这可能为肥胖患者乳腺癌预后研究开辟新方向。